Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration

Taeko Nagao1, Misako Kira1, Masako Takahashi2, Junko Honda3, Toshiyuki Hirose3, Akira Tangoku1, Hitoshi Zembutsu4, Yusuke Nakamura4 and Mitsunori Sasa*2

Address: 1Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15, Kuramotto-Cho, Tokushima 770-8509, Japan, 2Department of Surgery, Tokushima Breast Care Clinic, 4-7-7, Nakashimada-Cho, Tokushima 770-0052, Japan, 3Department of Surgery, National Higashi Tokushima Hospital, 1-1, Ohmukai-kita, Ootera, Itano, Tokushima 779-0193, Japan and 4Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-Ku, Tokyo 108-8639, Japan

Email: Taeko Nagao - tnagao@clin.med.tokushima-u.ac.jp; Misako Kira - kiramisa812@clin.med.tokushima-u.ac.jp; Masako Takahashi - takapy55@tune.ocn.ne.jp; Junko Honda - jhonda@higashitokushima.hosp.go.jp; Toshiyuki Hirose - tohirose@tpn.gr.jp; Akira Tangoku - tangoku@clin.med.tokushima-u.ac.jp; Hitoshi Zembutsu - zembutsu@ims.u.tokyo.ac.jp; Yusuke Nakamura - yusuke@ims.u-tokyo.ac.jp; Mitsunori Sasa* - breast@mb.tcn.ne.jp

* Corresponding author

Abstract

Background: Aromatase inhibitor (AI) therapy is being extensively used as postoperative adjuvant therapy in patients with hormone receptor-positive postmenopausal breast cancer. On the other hand, it has been reported that ovarian function was restored when AI was administered to patients who had undergone chemical menopause with chemotherapy or tamoxifen. However, there have been no reports of comprehensive monitoring of estradiol (E2) in breast cancer patients with ordinary menopause who were being administered AI.

Patients and Methods: Beginning in March 2008, regular monitoring of the serum levels of E2, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) was performed for 66 postmenopausal breast cancer patients who had been started on AI therapy. For this study, we chose anastrozole as the AI. The assays of those hormones were outsourced to a commercial clinical laboratory.

Results: In 4 of the 66 patients the serum E2 level was decreased at 3 months but had then increased at 6 months, while in 2 other patients E2 was decreased at both 3 and 6 months but had increased at 9 months.

Conclusion: The results indicate that, in some breast cancer patients with ordinary menopause, E2 rebounds following AI therapy. In the future, E2 monitoring should be performed for a larger number of patients being administered AI therapy.

Trial registration: Our trial registration number is 19-11-1211.

Published: 12 November 2009
Received: 8 July 2009
Accepted: 12 November 2009

This article is available from: http://www.wjso.com/content/7/1/88

© 2009 Nagao et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Approximately 60~70% of breast cancers are hormone receptor-positive, and tamoxifen (TAM) has been extensively used as postoperative adjuvant therapy. More recently, aromatase inhibitors (AIs) have been developed, and they have greatly altered the therapeutic strategy for hormone receptor-positive postmenopausal breast cancer [1,2]. The results of large-scale clinical studies have demonstrated that AI therapy is more useful than TAM, and today AIs are widely employed as standard therapy such as by switching from TAM to an AI, performance of extended AI therapy after 5-year administration of TAM, and as a first-line agent as postoperative adjuvant therapy [3-8]. On the other hand, it has been reported that ovarian function was restored in some patients when AI was administered to patients who had undergone chemical menopause by means of chemotherapy or TAM [9-11]. AI expresses its antitumor effect by reducing the serum level of estradiol (E2), and clinical efficacy of AI cannot be expected in patients in whom the E2 level does not decrease in response to AI. Such special patients have been reported, but there have been no reports of E2 monitoring in patients who underwent ordinary menopause and were administered AI as adjuvant therapy for breast cancer. Accordingly, beginning in March 2008, we performed regular monitoring of the serum level of E2, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in postmenopausal breast cancer patients who were administered an AI.

Patients and Methods
The patients included in this study were 66 patients who had been started on AI therapy between March 2008 and February 2009 at Tokushima Breast Care Clinic and underwent regular monitoring of their clinical course and for whom detailed clinicopathological studies were possible. In this study, we administered only anastrozole as an AI. The patient compliance in ingesting the AI was verbally confirmed, and patients with poor compliance were excluded from this study. Each patient was administrated anastrozole 1 mg/body p.o. once daily. Testing and evaluation of estrogen receptor (ER), progesterone receptor (PgR) and human epithelial growth factor receptor type 2 (HER2; Hercep Test, Dako) were performed by the conventional immunohistochemical methods [12]. At Tokushima Breast Care Clinic, the criterion for indication of AI administration is hormone receptor-positive, postmenopausal breast cancer. Menopause was defined as the state of having undergone bilateral oophorectomy, or women aged 60 years or older, aged under 60 years with amenorrhea for at least 12 months, and serum E2, LH and FSH levels satisfying the diagnostic criteria for postmenopause. The 66 patients entered in the present study consisted of 65 women who received the AI as postoperative adjuvant therapy and one woman who received the AI as preoperative therapy. The clinical disease stage showed a range of I-IV, and the surgical procedures consisted of mastectomy in 12 patients, breast-conserving surgery in 53 patients and only core needle biopsy in one patient. Prior to administration of the AI, 12 patients had been administered TAM, 9 patients had undergone chemotherapy, and 5 patients had received both chemotherapy and TAM. The remaining 40 patients were treated only with the AI (Additional File 1).

The serum levels of E2, LH and FSH were assayed prior to administration of the AI and then at 3, 6, 9 and 12 months after starting the AI therapy. Those assays were performed by FALCO Biosystems Ltd. (Kyoto, JAPAN), and serum E2, LH and FSH levels were measured by ECLIA (Electrochemiluminescence Immunoassay) in this laboratory. The laboratory’s standard values for the postmenopausal levels of those hormones are 10-40 pg/ml for E2 (lower limit of detection: 5 pg/ml), 7.7-58.5 mIU/ml for LH and 25.8-134.8 mIU/ml for FSH.

Statistical analyses were performed using the chi-square test and the Wilcoxon signed ranks test, and a p value of <0.05 was defined as indicating significance.

The design of this study was approved by the Ethics Committee of The Institute of Medical Science, The University of Tokyo, and The University of Tokushima. Prior informed consent was obtained in writing from each of the enrolled patients.

Results
The mean observation time for the patients was 5.9 months. Additional File 2 shows the data for the serum levels of E2, LH and FSH for all of the patients. Because the lower limit of detection for E2 was 5 pg/ml, values of 5 pg/ml or less were recorded as 5 pg/ml. The baseline value of E2 (i.e., prior to AI administration) was already at the lower limit of detection (5 pg/ml) in 24 (36%) of the patients. The mean E2 level was significantly reduced at both 3 months (5.3 ± 0.8 pg/ml) and 6 months (5.7 ± 1.7 pg/ml) after the start of AI administration compared with the mean baseline value (7.8 ± 3.3 pg/ml). However, in 4 patients the E2 level had increased again at 6 months even though it had been clearly decreased at 3 months after the start of AI administration, while in 2 other patients the E2 level had increased again at 9 months in spite of having been decreased through 6 months after starting AI administration (Fig. 1). In addition, the assay results also showed that, due to the administration of the AI, the mean serum level of FSH was significantly increased from the baseline value of 55.3 ± 31.3 pg/ml to 65.3 ± 32.6 pg/ml after 3 months and 65.4 ± 35.4 pg/ml after 6 months. The mean serum level of LH was also observed to increase with time following the start of AI administration, but
there was no clearly significant difference compared with
the baseline (Additional File 2). In 5 of these 6 patients
with E2 rebound, the FSH level was increased at 3 months
after the start of AI administration, while in one patient
FSH was not changed. In addition, the LH level was
increased in 2 of those patients, unchanged in 2 patients
and decreased in the remaining 2 patients.

Additional File 1 presents a comparison of the clinico-
pathological findings for the patients whose serum E2 was
continuously decreased after the start of AI administration
and the patients whose E2 level later rebounded. The clin-
cical disease stage was 0 or I in each of the patients whose
E2 rebounded. The E2 showed a continuous decrease in
60 of the patients, 25 (41.7%) of whom had undergone
some sort of therapy prior to AI administration, whereas
only one (16.7%) of the patients with E2 rebound had
undergone prior therapy. Next, we examined for correla-
tions between the serum E2 level and the age at menarche,
the number of years since menopause, the number of
births and the body mass index (BMI) of the patients. The
mean age at menarche was 15.5 ± 1.2 years in the patients
with E2 rebound, which was significantly higher than the
mean age of 13.7 ± 1.6 years in the patients with continu-
ous E2 reduction. Moreover, although the difference did
not reach statistical significance, the number of births
experienced by the women showing E2 rebound was
smaller (Additional File 3).

Discussion

The advent of AIs marked a revolution in the therapeutic
approach to postmenopausal, hormone receptor-positive
breast cancer [1,2]. AIs include three third-generation
compounds, anastrozole, exemestane and letrozole, and
large-scale clinical trials have been carried out on each [3-
8]. Based on the results of those trials, AIs have come to be
extensively used to treat hormone receptor-positive, post-
menopausal breast cancer. AI therapy brings about an
approximately 90% reduction in the serum and tumor-tis-
sue levels of E2 in postmenopausal women, which is the
basis of the expression of the antitumor effects of AIs on
hormone receptor-positive breast cancer cells [13-17]. On
the other hand, there have been reports that AI adminis-
tration led to restoration of the ovarian function in some

Figure 1

Serum E2 level in cases with E2 rebounded. In 4 patients (Nos. 2, 3, 5, 6), the E2 level had increased at 6 months after
starting AI (anastrozole) therapy, and in 2 patients (Nos. 1, 4), the E2 level had increased at 9 months after starting AI therapy.
patients with chemically induced menopause or whose ovarian function was being suppressed by administration of TAM [9-11]. Those can be thought to be special cases in which menstruation was restarted due to AI administration after chemical menopause had been induced in premenopausal patients by chemotherapy or TAM administration. However, there have been no reports of comprehensive monitoring of E2 in breast cancer patients who had undergone ordinary menopause and were being administered an AI. For that reason, we initiated the present clinical study in March 2008 to monitor and analyze the serum levels of E2, LH and FSH in postmenopausal breast cancer patients who were started on AI (anastrozole) therapy. The assays of those serum hormone levels were subcontracted to an outside, government-licensed commercial clinical laboratory. The assay results indicated the possibility that the serum E2 level rebounds in some postmenopausal women due to administration of an AI. The E2 level shows circular rhythm, but we did not investigate that in this study. Moreover, intra- and inter-assay error values may occur with this ECLIA assay. We also did not investigate the precision of the ECLIA method. However, it is at least clear that in these patients the reduction of E2 that can be expected due to the effects of AI therapy is not being achieved. As one potential reason for this phenomenon, we surmised the possibility that there is some residual ovarian function in those patients even though they were thought to be clinically postmenopausal, and that a negative feedback due to the E2 reduction induced by administration of an AI leads to E2 secretion from the residual ovarian tissue in response to stimulation with LH and FSH. Almost all of the patients in this study who showed renewed elevation of serum E2 had not undergone any prior therapy and were administered only the AI, and the results indicate the possibility that they possessed residual ovarian function in spite of being approximately 60 years of age. Therefore, defining "postmenopausal" only on the basis of an age of "60 years" may be erroneous. Moreover, it was indicated that there is a possibility of greater residual ovarian function in patients in whom the age of menarche is delayed. On the other hand, it can be surmised that administration of chemotherapy or TAM will further suppress any residual ovarian function in women who would ordinarily be assumed to be postmenopausal on the basis of their age, and that, due to the complete absence of residual ovarian function, administration of an AI would result in continuous inhibition of serum E2. The data generated in the clinical studies of AIs did not show any patients in whom the AI administration led to renewed elevation of E2 [13-16]. We assume that the reason for this is that most of the patients enrolled in those clinical trials had advanced, postmenopausal, recurrent breast cancer and that almost all had undergone prior treatment using chemotherapy and/or TAM. Moreover, it can be thought that there is a possibility that the inhibition of serum E2 was continuous in all of those study patients. Also, in women who had undergone pretreatment with chemotherapy and/or TAM prior to menopause, a revised definition may be necessary for "postmenopausal". As another potential reason, we postulate the possibility that, in some patients, the expression of the effects of AI therapy is inadequate due to a genetic aberration in relation to an AI-metabolizing enzyme such as CYP19 (aromatase P450) [18,19]. We hope that future studies will be carried out to clarify this issue.

For this study, the lower limit of detection for serum E2 was 5 pg/mL. Based on the study results, it can be concluded that the serum E2 level was 5 pg/mL or less even before AI administration in approximately 36% of the patients who were judged to be clinically postmenopausal. That incidence needs to be further investigated by means of a more sensitive assay method. In such patients, any further decrease in serum E2 cannot be detected.

The limitations of this study are the small number of enrolled patients and the rather short follow-up time of approximately one-half year. In addition, as an AI, only anastrozole was administered and investigated. Nevertheless, we surmise that, since AIs are poised to play a key role in the treatment of postmenopausal hormone receptor-positive breast cancer patients, it is necessary to carry out further investigation of the effects of AI therapy on the serum E2 level by performing E2 monitoring in a much larger number of patients.

**Abbreviations**

AI: aromatase inhibitor; E2: estradiol; LH: luteinizing hormone; FSH: follicle-stimulating hormone; TAM: tamoxifen; ER: estrogen receptor; PgR: progesterone receptor; HER2: human epithelial growth factor receptor type 2; ECLIA: Electrochemiluminescence immunoassay

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MS initiated and co-wrote the paper with TN, MK and AT. MT, JH, and HT took part in the care of patients. ZH and YN helped in preparation of the manuscript. All authors read and approved the manuscript.

**References**

1. Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H, Panel Members: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. *Ann Oncol* 2007, 18:1133-1144.

2. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Grlasow J, Cobleigh MA, Mamounas EP, Goldstein L, Whelan TJ, Powles TJ, Bryant J, Perkins C, Poroi J, Braun S, Langer AS, Brown GP, Somerfield MR. American society of clinical oncology technology assessment on the
use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer. Status report 2004. J Clin Oncol 2005; 23:19-629.
3. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45-53.
4. Costes AS, Kashaviah A, Thirlimba B, Mouridsen H, Mauric L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Mastro LD, Smith I, Chirgwin J, Nogaret J, Pieroniowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsh A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25:486-492.
5. Coombes RC, Kirkbride S, Snowden CF, Paridaens R, Coleman RE, Jones SE, Jass J, Velde CJH, Delozier T, Alvarez I, Mastro L, Ortman O, Dierich K, Coopers AS, Bajetta E, Holmgren SB, Dodwell D, Miekiewicz E, Andersen J, Lennings PE, Cocco G, Forbes J, Castiglione-Moore N, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JMF, on behalf of the Intergroup Exemestane Study: Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup exemestane study): a randomized controlled trial. Lancet 2007; 369:559-570.
6. Jakesz R, Jonat W, Gnant M, Münstedt K, Aapro M, Aapro MS, Anker G, Dowsett M, Geisler J, Kauffmann M, on behalf of the ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart M, Castiglione-Moore N, Tu D, Shepherd LE, Pritchard KI, Livshits B, Rikhardsson F, Mackewe C, Scudds J, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as initial adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 2006; 98:1162.
8. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kabets K, Schelft M, Gademann G, Kaufmann M, on behalf of the ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
9. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart M, Castiglione-Moore N, Tu D, Shepherd LE, Pritchard KI, Livshits B, Rikhardsson F, Mackewe C, Scudds J, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as initial adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 2006; 98:1162.
10. Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K: Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme CYP17 and CYPI9 with breast cancer risk in Chinese women. Breast Cancer Res Treat 2009; 114:327-338.